Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387814 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02387814 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants.
The verdict
NCT02387814, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment compared to healthy participants. In addition, the tolerability of the study drug will be evaluated. This study will last approximately 3 weeks for each participant, including check-in and follow-up.
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02387814
The ClinicalTrials.gov registry entry for NCT02387814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT02387814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02387814 about?
NCT02387814 is a clinical study titled "A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment". The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment comp...
What is the current status of trial NCT02387814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2015-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02387814?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT02387814?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.